ters with patients who were nonwhite (eg, African American [OR, 0.88; 95% CI, Table 2 ). We observed substantial clinician variation with 17% never using steroid injections and 13% of clinicians using an injection more than 40% of the time (data not shown).
1. CDC Adult Treatment Recommendations. https://www.cdc.gov/getsmart /community/for-hcp/outpatient-hcp/adult-treatment-rec.html. Accessed July 17, 2017. These observations are based on administrative data that may be incomplete or inaccurate. However, the data are alarming given that there is no evidence that treatment with steroids is of benefit for acute respiratory infection, and even short courses of steroids can cause harmful adverse effects. We believe additional research is needed to confirm the inappropriate use of steroids in patients with acute respiratory infection, and if confirmed, we look forward to learning about interventions to minimize such use. Because this practice has no known benefit and definite harms, it is classified in our Less Is More series.
Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries
Physicians and teaching hospitals in the United States receive approximately $7 billion from the pharmaceutical industry annually. 1 These payments have been associated with higher-cost, brand-name pharmaceutical prescribing. [2] [3] [4] Whether industry payments are associated with physician treatment choice in oncology is uncertain. We examined the association between oncologists' receipt of payments from pharmaceutical manufacturers and drug selection in 2 situations where there are multiple treatment options. Payments using the National Provider Identifier and practice location via the National Plan and Provider Enumeration System. This study was exempted from review by the University of North Carolina institutional review board as not constituting human participants research. We considered on-patent drugs that were within the same therapeutic class; had US Food and Drug Administration approval and National Comprehensive Cancer Network recommendation for treatment of a cancer of a given site, stage, and degree of previous treatment; and were prescribed by at least 10 physicians in 2014. This resulted in the following 2 sets of drugs: sorafenib, sunitinib malate, and pazopanib hydrochloride (metastatic renal cell cancer [mRCC] group) and dasatinib, imatinib mesylate, and nilotinib hydrochloride monohydrate (chronic myeloid leukemia [CML] group).
We included physicians with a provider type of oncologist and at least 20 filled prescriptions among the respective 3 drugs in 2014. For each physician, we included all general payments from each drug manufacturer. We attributed research payments to physicians identified as principal investigators. Our primary exposure was payments received during 2013 (yes or no), and the primary outcome was prescriptions filled during 2014; we also analyzed payments as a continuous variable. We used the conditional logit model by McFadden to test whether receipt of payments from a manufacturer was associated with increased relative prescribing of that manufacturer's drug within the choice set of multiple drugs. Separately, we evaluated drug-specific results using multivariable logistic regression, controlling for physician age, region, practice size, and prescribing volume. Separate models were estimated for general payments and research payments.
Results | Among 354 physicians who prescribed mRCC drugs and 2225 physicians who prescribed CML drugs, we found increased odds of prescribing a manufacturer's drug among physicians receiving general payments only or either payment type (Table) . Of physicians prescribing the drugs, 9.0% (32 of 354) of those prescribing for mRCC and 3.8% (38 of 2225) of those prescribing for CML received research payments in both 2013 A and B, Multivariable logistic regression was used to estimate the association between receipt of manufacturer payments and physicians' prescribing of that manufacturer's drug. Each bar represents the market share for a specific drug (the probability of using the drug of interest relative to the other included treatments). Physicians who received payments from the manufacturer of the drug of interest are shown in light blue; physicians who did not are shown in dark blue. Results are adjusted for physician age, region, practice size, prescribing volume, and year of medical school graduation. Sunitinib was given as sunitinib malate; pazopanib as pazopanib hydrochloride; imatinib as imatinib mesylate; and nilotinib as nilotinib hydrochloride monohydrate. a P < .05. The model was able to accommodate physicians who received payments from more than one of the relevant companies; they were treated as having experienced the primary exposure for each company from which they received payments. All results are adjusted for physician region, practice size, prescribing volume, and year of medical school graduation. b Because payment data are skewed, we used a natural log transformation for estimating the association between increasing US dollar amounts of payments and prescribing. and 2014, compared with 25.1% (89 of 354) and 39.5% (879 of 2225) for general payments, respectively. Receipt of research payments was associated with increased prescribing for mRCC but not CML. Similarly, when treating payments as a continuous variable, increasing amounts of general payments were associated with increased prescribing. Considering individual drugs, we found increased prescribing when receiving vs not receiving general payments for sunitinib (50.5% vs 34.4%, P = .01), dasatinib (13.8% vs 11.4%, P = .02), and nilotinib (15.4% vs 12.5%, P = .01) (Figure) but found decreased prescribing of imatinib (72.4% vs 75.5%, P = .02). Differences for sorafenib and pazopanib were not statistically significant. Research payments were not associated with statistically significant differences in prescribing for any individual drug. Results were similar when including payments specifically attributed to the drug of interest rather than all payments from the corresponding manufacturer and when changing the exposure to receipt of payments in both 2013 and 2014 (vs 2013 without respect to 2014). Our study had some limitations. These include the observational design precluding causal assessment, potential inaccuracies with Open Payments data, 5 lack of generalizability to other cancers, absence of information about the indications for the drugs, and small sample sizes for comparisons in the research payments analysis, notably for physicians receiving CML research payments.
Conclusions | For 3 of the 6 cancer drugs studied, physicians who received general payments were more likely to prescribe the drug marketed by the company that made the payments. Imatinib was a notable exception; this may reflect a strategy by the manufacturer of imatinib (which also produces nilotinib) to promote switching to nilotinib before the patent expiration of imatinib in 2015.
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Correlates and Outcomes of Physician Burnout Within a Large Academic Medical Center
Physician burnout is increasingly recognized as a systemic health care problem. 1 Prior research has identified the adverse impact on physician health and patient care. 2 Recently, studies have begun to examine the impact on health care delivery. 3 We assessed the correlates and outcomes of physician burnout in a single health system.
Methods | Data for this study come from the Cleveland Clinic Health System, a large nonprofit academic health system. Physicians completed the Maslach Burnout Inventory prior to a mandatory communication skills course between August 1, 2013, and May 1, 2014. The Maslach Burnout Inventory measured burnout in 3 domains: emotional exhaustion, depersonalization, and personal accomplishment, as well as burnout overall (defined as emotional exhaustion ≥27 and/or depersonalization ≥10). 4 Outcomes included leaving the organization, productivity, receipt of ombudsman complaints, and patient satisfaction with physician communication in inpatient, primary care, and specialty care. Employment-related data were provided by the Office of Professional Staff Affairs. Patient satisfaction was assessed via Consumer Assessment of Healthcare Providers and Systems surveys tied to the discharge or outpatient physician seen. 5, 6 Data were entered into a registry approved by the Cleveland Clinic Institutional Review Board. All participants had the option to exclude their data from the registry. The study, which used existing data, was deemed exempt from institutional review board approval.
We assessed correlates of burnout overall and for the emotional exhaustion and depersonalization subscales using
